ABSTRACT
Importance There is a pressing need to understand the biology of Parkinson’s disease (PD) progression and to identify biological pathways as possible therapeutic targets.
Objective To identify genomic variation associated with PD motor presentation and early stage progression.
Design GWAS meta-analysis of early PD motor progression, from multiple longitudinal cohorts, using MDS-UPDRS III clinical assessments.
Setting Multicentre
Participants 3572 unrelated European ancestry individuals diagnosed with PD from 6 studies.
Main Outcomes and Measures Linear mixed effect models under an additive model corrected for age at diagnosis, gender, and the first 5 genetic principal components (PCs), with axial, limb, and total MDS-UPDRS III as outcomes of the model.
Results We identified an association between the PD axial rate of progression and variation at the GJA5 locus at 1q12 (Beta = -0.25, SE = 0.04, P = 3.4e-10). Exploration of the regulation of gene expression in the region (cis-eQTL analysis) showed that the lead variant was associated with expression of ACP6, a lysophosphatidic acid phosphatase that regulates mitochondrial lipid biosynthesis (cis-eQTLs p-values in blood and brain RNA expression datasets: < 10−8 in eQTLGen and 10−7 in PsychEncode). In addition, we found a nominal association between axial motor presentation and the MAD1L1 gene at 7q21.11 (Beta = 0.54, SE = 0.11, P = 1.6e-7), a gene previously associated with neuropsychiatric disease, and in the long non-coding RNA LINC00511 at 17q21.31 (Beta = -0.62, SE = 0.11, P = 6.3e-8). Further functional annotation allowed us to nominate the likely causal variants and determine that variants at 7q21.11 may be related to dysregulation of MAD1L1 expression. Variants at LINC00511 may cause a disruption of a distal epigenetic regulation of SOX9 through an anchored chromatin loop.
Conclusions and Relevance Our large multicentre study sheds new light on the genetic architecture of PD progression, which is distinct from PD susceptibility. Our study highlights the potential role of mitochondrial lipid homeostasis in the progression of PD, which may be important in establishing new drug targets to tackle disease progression.
Competing Interest Statement
H.R.M. reports paid consultancy from Roche. Research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, CBD Solutions, Drake Foundation, Medical Research Council (MRC), Michael J. Fox Foundation. Dr Morris is a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). D.G.G. has received grants from Michael's Movers, the Neurosciences Foundation, and Parkinson's UK, and honoraria from AbbVie, BIAL Pharma, Britannia Pharmaceuticals, GE Healthcare, and consultancy fees from Acorda Therapeutics and the Glasgow Memory Clinic. M.T.M.H. received funding/grant support from Parkinson's UK, Oxford NIHR BRC, University of Oxford, CPT, Lab10X, NIHR, Michael J. Fox Foundation, H2020 European Union, GE Healthcare and the PSP Association. She also received payment for Advisory Board attendance/consultancy for Biogen, Roche, Sanofi, CuraSen Therapeutics, Evidera, Manus Neurodynamica, Lundbeck. Y.B.-S. has received grant funding from the MRC, NIHR, Parkinson's UK, NIH, and ESRC. CC receives salary from University Hospitals Plymouth NHS Trust and National Institute of Health and Care Research. She has received advisory, consulting or lecture fees from AbbVie, Bial, Scient, Orkyn, Abidetex, UCB, Pfizer, EverPharma, Lundbeck, Global Kinetics, Kyowa Kirin, Britannia and Medscape, and research funding from Parkinson's UK, Edmond J Safra Foundation, National Institute of Health and Care Research and Cure Parkinson's. J.C.C. has served on advisory boards for Biogen, Denali, Idorsia, Prevail Therapeutic, Servier, Theranexus, UCB, and received grants from Sanofi and the Michael J. Fox Foundation outside of this work. A.E. received funding/grant support by Agence Nationale de la Recherche, France Parkinson, and the Michael J. Fox foundation. J.H. is supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. He is also supported by the MRC, Wellcome Trust, Dolby Family Fund, National Institute for Health Research University College London Hospitals Biomedical Research Centre. All other authors report no competing interests.
Clinical Protocols
https://github.com/AMCalejandro/EMPD
Funding Statement
This research was funded in whole or in part by Aligning Science Across Parkinson's [Grant number: ASAP-000478] through the Michael J. Fox Foundation for Parkinson's Research (MJFF). For the purpose of open access, the author has applied a CC BY public copyright licence to all Author Accepted Manuscripts arising from this submission.
This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation. Both TPD and OPDC cohorts are primarily funded and supported by Parkinson's UK and supported by the National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). The TPD study is also supported by NHS Greater Glasgow and Clyde. The OPDC cohort is also supported by the NIHR Oxford Biomedical Research Centre, based at the Oxford University Hospitals NHS Trust, and the University of Oxford. The DIGPD cohort is sponsored by Assistance Publique Hopitaux de Paris, funded by a grant from the French Ministry of Health (PHRC 2008, AOR0810) and a grant from the Agence Nationale de Securite et des Medicaments (ANSM-2013). PD-STAT is funded and supported by grants from the Cure Parkinson's Trust and JP Moulton Charitable Foundation, co-ordinated by the Peninsula Clinical Trials Unit, University of Plymouth and sponsored by University Hospitals Plymouth NHS Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
TPD has multi-centre research ethics approval from the West of Scotland Research Ethics Committee (REC reference: 11/AL/0163). OPDC has multi-centre research ethics approval from the South Central Oxford A Research Ethics Committee (REC reference: 16/SC/0108). AMP-PD clinical data collection and DNA samples were obtained with local institutional and ethical approvals (details can be obtained from the https://amp-pd.org and each study website). DIGPD was sponsored by Assistance Publique Hopitaux de Paris and approved by French regulatory authorities (NCT01564992). PD-STAT has been approved by the North East-Newcastle and North Tyneside 2 Research Ethics Committee (NCT02787590). All subjects provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Alejandro Martinez-Carrasco: alejandro.carrasco.20{at}ucl.ac.uk; Raquel Real: r.real{at}ucl.ac.uk; Michael Lawton: Michael.Lawton{at}bristol.ac.uk; Regina Reynolds: regina.reynolds.16{at}ucl.ac.uk; Manuela Tan: manuela.tan{at}medisin.uio.no; Lesley Wu: l.wu.17{at}ucl.ac.uk; Nigel Williams: williamsnm{at}cardiff.ac.uk; Camille Carroll: camille.carroll{at}plymouth.ac.uk; Jean-Christophe Corvol: jean-christophe.corvol{at}aphp.fr; Michelle Hu: michele.hu{at}ndcn.ox.ac.uk; Donald Grosset: donaldgrosset{at}gmail.com; John Hardy: j.hardy{at}ucl.ac.uk; Yoav Ben shlomo: y.ben-shlomo{at}bristol.ac.uk; Maryam Shoai: m.shoai{at}ucl.ac.uk; Huw Morris: h.morris{at}ucl.ac.uk